Professional Documents
Culture Documents
.WHO - Stability - Testing. 2007
.WHO - Stability - Testing. 2007
Training Workshop on
Pharmaceutical Development with
focus on Paediatric Formulations
Tallinn
15-19th October 2007
We will:
Review relevant guidelines
Formulation
Packaging
Batch size
Container labelling
Changes to product
- Development studies
- Characterise compatibility with common excipients
- Characterise stability profile of API
- Eg susceptibility to acid, base, light, oxygen etc……
- Characterise stability profile of early formulations
- Especially susceptibility to heat, humidity & light
- Confirmatory studies
- Long term & accelerated studies on the product as it is to be registered
- In practice design is now largely dictated by ICH guidelines
Whilst ICH guidelines are more detailed than those of WHO, there are few
‘in-principle’ differences, except in relation to testing conditions for hot &
humid climates
Available via
http://www.ich.org/cache/compo/276-254-1.html
Note:
– Applies to ‘Well established drug substances’
– Applies to ‘Conventional dosage forms’
– These guidelines are under revision : See h
ttp://www.who.int/medicines/services/expertcommittees/pharmp
rep/41ec_meet/en/index.html
Training Workshop on Pharmaceutical Development
Slide 12
with a Focus on Paediatric Medicines 15-19 October 2007
WHO stability guidelines - 2
- Production batch:
- A batch manufactured at production scale using production
equipment & in a production facility as specified in the
registration application
- Accelerated testing
- Studies designed to increase the rate of chemical degradation or physical
change by means of exaggerated storage conditions
- Intermediate testing
- Studies at 30degC/60%RH, intended for extrapolation to long term storage at
25degC [provided that 25degC is appropriate for the market in question]
- Stress testing
- API: Studies which elucidate intrinsic stab of API. Normally during development.
Normally more stressful than ‘accelerated’ testing.
- Finished product: Studies of effect of ‘severe’ conditions. Eg freeze/thaw cycling
for suspensions & emulsions, low humidity for aqueous liquids in moisture-
permeable containers.
Climatic zones:
– Partition of the world into three temperature classes based
on kinetic averaging of monthly temperatures, &
subdivision of the hottest class into predominantly wet or
predominantly dry
– Zones (Futscher & Schumacher 1972):
• I Temperate (21oC/45%RH)
• II Subtropical (25oC/60%RH with possibly high RH)
• III Hot & dry (30oC/35%RH)
• IV Hot & wet (30oC/70%RH)
– The temperatures above are kinetic averages
“The Secretariat reminded the Committee that the WHO guidelines had
been revised in the light of harmonization efforts in collaboration with
ICH. Subsequently focus had been placed within regional
harmonization initiatives on the recommendations for hot and humid
conditions (referred to as Zone IV). After extensive discussion the
Committee reached consensus that the WHO stability guidelines be
amended to reflect conditions for Zone IV as follows:
— Zone IVa (30 degrees Celsius and 65% relative humidity); and
— Zone IVb (30 degrees Celsius and 75% relative humidity).
It was agreed that each individual Member State within the former
Zone IV would need to indicate whether its territory should be
classified as Zone IVa or IVb.”
T = Sample is tested
T = Sample is tested
- Container size?
- Batch size?
- Formulation of coating?
ICH: “It is up to the applicant to decide whether long term stability studies are
performed at 25oC ±2oC/60%RH ±5%RH or 30oC ±2oC/65%RH
±5%RH.”
- Chemical
- Physical
- Microbiological
- Leaching
- Absorption (into container walls)
- Adsorption (on to container walls)
- Volatilisation (eg sertraline base, glyceryl trinitrate)
- Altered particle size distribution
- Loss of higher order molecular structure (normally
only for biological medicines)
- Denaturation
- Aggregation
- Some examples:
- When prone to adsorption on to, or absorption into,
packaging materials, use resistant packaging
materials, such as good quality glass
- When prone to volatilisation:
- Use a non-volatile salt (if possible)
- Use packaging materials that are resistant to vapour transfer
- When prone to altered particle size in suspensions:
- Formulate a continuous phase in which the active is less soluble
- Release limits
- Expiry limits
Poolability
Perform statistical
test for common slope
- Regulatory guidelines